Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum
Waldencast Acquisition Corp. - Class A Ordinary Share (WALD)
Company Research
Source: GlobeNewswire
NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), the fastest growing professional skincare brand in the U.S. in 2024*, proudly unveils its latest innovation rooted in clinical skin science: Nu-Cil® BioStim™ Scalp Serum. Designed to promote a healthier scalp, the foundation of fuller, stronger hair, this advanced leave-in serum is clinically proven to reduce dry, fallen hair by 74% in just three months, helping deliver visibly denser, fuller-looking strands. The Nu-Cil® BioStim™ Scalp Serum expands on Obagi’s 35 years of skin health expertise and leadership in medical-grade innovation by applying its skin first philosophy to the scalp through the BioStim™ Complex. The BioStim™ Complex utilizes proprietary technology powered by a synergistic blend of clinically proven actives, including Biotin, Amino Acids, and Peptides – alongside 18 essential Nutrients, B Vitamins, and Phytoactives. These actives work to promote scalp health, fortify hair follicles, and strength
Show less
Read more
Impact Snapshot
Event Time:
WALD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WALD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WALD alerts
High impacting Waldencast Acquisition Corp. - Class A Ordinary Share news events
Weekly update
A roundup of the hottest topics
WALD
News
- How Recent Developments Are Shaping the Waldencast Investment Story [Yahoo! Finance]Yahoo! Finance
- Waldencast (NASDAQ:WALD) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $5.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Waldencast (NASDAQ:WALD) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- Waldencast (NASDAQ:WALD) was downgraded by analysts at Telsey Advisory Group from an "outperform" rating to a "market perform" rating.MarketBeat
- Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading UpdateGlobeNewswire
WALD
Sec Filings
- 12/4/25 - Form F-3
- 11/24/25 - Form 6-K
- 11/24/25 - Form 6-K
- WALD's page on the SEC website